Patent Oppositions in medicinal compounds for specific treatments industry

Explore the competitive field of medicinal compounds for specific treatments where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in medicinal compounds for specific treatments technology and learn how to protect your intellectual property.

Get Patent Opposition Report for medicinal compounds for specific treatments

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Report

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Last updated on: Oct 2, 2025
CompanyTotal Oppositions
NOVARTIS286
BOEHRINGER INGELHEIM107
AMGEN81
NOVO NORDISK75
PFIZER75
NESTLE62
NUTRICIA60
NESTEC54
JANSSEN PHARMACEUTICA53
BRISTOL MYERS SQUIBB47

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the medicinal compounds for specific treatments industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the medicinal compounds for specific treatments industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition DateOpposition Name

Get alerts on new patent oppositions in the medicinal compounds for specific treatments industry

Method For Treating Multiple SclerosisF HOFFMANN LA ROCHEAug 27, 2025HEXAL
Methods Of Using A Bispecific Antibody That Recognizes Coagulation Factor Ix And/Or Activated Coagulation Factor Ix And Coagulation Factor X And/Or Activated Coagulation Factor XCHUGAI SEIYAKU KABUSHIKI KAISHAAug 27, 2025J A KEMP
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKAug 27, 2025DR REDDYS LABORATORIES
Method For Preventing Or Treating Osteoporosis Characterized By Administering Teriparatide Or Salt Thereof Twice A WeekASAHI KASEI PHARMAAug 27, 2025GENERICS UK
Method For Treating Multiple SclerosisF HOFFMANN LA ROCHEAug 26, 2025POLPHARMA BIOLOGICS
Methods Of Using A Bispecific Antibody That Recognizes Coagulation Factor Ix And/Or Activated Coagulation Factor Ix And Coagulation Factor X And/Or Activated Coagulation Factor XCHUGAI SEIYAKU KABUSHIKI KAISHAAug 26, 2025MAIWALD
Methods Of Using A Bispecific Antibody That Recognizes Coagulation Factor Ix And/Or Activated Coagulation Factor Ix And Coagulation Factor X And/Or Activated Coagulation Factor XCHUGAI SEIYAKU KABUSHIKI KAISHAAug 25, 2025WUESTHOFF & WUESTHOFF
Preparation Containing Tetracyclic Compound At High DoseCHUGAI SEIYAKU KABUSHIKI KAISHAAug 20, 2025ELKINGTON AND FIFE
Preparation Containing Tetracyclic Compound At High DoseCHUGAI SEIYAKU KABUSHIKI KAISHAAug 19, 2025TEVA PHARMACEUTICALS
Use Of Migalostat In Reducing The Risk Of Cerebrovascular Event In Patients With Fabry DiseaseAMICUS THERAPEUTICSAug 13, 2025BRAND MURRAY FULLER

To stay ahead in the competitive medicinal compounds for specific treatments industry, companies are constantly innovating. Here are the top patents facing oppositions in the medicinal compounds for specific treatments industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS23
Apr 14, 2021Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY22
Nov 6, 2024Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICA20
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM18
Oct 23, 2024New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTIS18
Oct 11, 2023New UseNOVARTIS16
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE15
Mar 8, 2023Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTIS15
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI13
Nov 13, 2019Apixaban FormulationsBRISTOL MYERS SQUIBB IRELAND12